O'Connor, James P. B.
Aboagye, Eric O.
Adams, Judith E.
Aerts, Hugo J. W. L.
Barrington, Sally F.
Beer, Ambros J.
Boellaard, Ronald
Bohndiek, Sarah E.
Brady, Michael
Brown, Gina
Buckley, David L.
Chenevert, Thomas L.
Clarke, Laurence P.
Collette, Sandra
Cook, Gary J.
deSouza, Nandita M.
Dickson, John C.
Dive, Caroline
Evelhoch, Jeffrey L.
Faivre-Finn, Corinne
Gallagher, Ferdia A.
Gilbert, Fiona J.
Gillies, Robert J.
Goh, Vicky
Griffiths, John R.
Groves, Ashley M.
Halligan, Steve
Harris, Adrian L.
Hawkes, David J.
Hoekstra, Otto S.
Huang, Erich P.
Hutton, Brian F.
Jackson, Edward F.
Jayson, Gordon C.
Jones, Andrew
Koh, Dow-Mu
Lacombe, Denis
Lambin, Philippe
Lassau, Nathalie
Leach, Martin O.
Lee, Ting-Yim
Leen, Edward L.
Lewis, Jason S.
Liu, Yan
Lythgoe, Mark F.
Manoharan, Prakash
Maxwell, Ross J.
Miles, Kenneth A.
Morgan, Bruno
Morris, Steve
Ng, Tony
Padhani, Anwar R.
Parker, Geoff J. M.
Partridge, Mike
Pathak, Arvind P.
Peet, Andrew C.
Punwani, Shonit
Reynolds, Andrew R.
Robinson, Simon P.
Shankar, Lalitha K.
Sharma, Ricky A.
Soloviev, Dmitry
Stroobants, Sigrid
Sullivan, Daniel C.
Taylor, Stuart A.
Tofts, Paul S.
Tozer, Gillian M.
van Herk, Marcel
Walker-Samuel, Simon
Wason, James
Williams, Kaye J.
Workman, Paul
Yankeelov, Thomas E.
Brindle, Kevin M.
McShane, Lisa M.
Jackson, Alan
Waterton, John C.
Article History
First Online: 11 October 2016
Competing interests
: J.P.B.O'C. (CRUK, Eli Lilly), H.J.W.L.A. (NIH), S.F.B. (AstraZeneca), R.B. (Philips), S.B. (CRUK), M.B. (CRUK, EPSRC), K.M.B. (CRUK, EPSRC, GE Healthcare), T.L.C. (NIH), S.C. (European Union FP7), G.J.C. (Alliance Medical, Bayer, Blue Earth Diagnostics, CRUK, GE Healthcare, Siemens Healthcare), N.M.dS. (CRUK, European Union FP7, NIHR), C.D. (CRUK), C.F-F. (AstraZeneca, Merck), F.A.G. (CRUK, GE, GSK), F.J.G. (CRUK, EPSRC), R.J.G. (NIH), V.G. (GE Healthcare, Siemens Healthcare), A.M.G. (GSK), A.L.H. (CRUK), D.J.H. (CRUK, EPSRC, Elekta, Philips, Truebeam), B.F.H. (GE Healthcare, Mediso, Siemens Healthcare), A.J. (CRUK, EPSRC), G.C.J. (AstraZeneca, Novartis, Oxigene, Roche), N.L. (Bracco), M.L. (CRUK, EPSRC), E.L.L. (GE Healthcare, Pfizer, Philips), J.S.L. (Eli Lilly, MabVAx Inc, NIH, The Curadel Companies), Y.L. (European Union FP7), T.N. (CRUK, EPSRC), A.R.P. (Acuitas Medical, Siemens Healthcare), G.J.M.P. (CRUK, EPSRC), M.P. (CRUK), A.C.P. (NIHR), R.A.S. (CRUK, HEFCE, MRC, Sirtex Technology), S.A.T. (NIHR), K.J.W. (Eli Lilly), P.W. (CRUK) and T.E.Y. (NIH) receive grants and financial support from the indicated sources. E.A. (Lightpoint Medical), H.J.W.L.A. (Genospace LLC), R.J.G. (HealthMyne Inc), T-Y.L. (GE Healthcare), K.A.M. (Imaging Endpoints), G.J.M.P. (GSK), R.A.S. (Affidea, BTG plc, Cancer Research Technology, Sirtex Medical, Vertex), D.C.S. (RSNA), S.A.T. (Robarts), M.vH. (Aquilab), P.W. (Astex Pharmaceuticals, Nextechinvest, Nuevolution) have acted as consultants for the indicated organizations. H.J.W.L.A. (Genospace LLC), J.L.E. (Merck & Co), R.J.G. (HealthMyne Inc), D.J.H. (IXICO PLC, visionRT), J.S.L. (pHLIP Inc), K.A.M. (Feedback PLC), G.J.M.P. (Bioxydyn Ltd), J.C.W. (Alderley Imaging Ltd, AstraZeneca), P.W. (Chroma Therapeutics, Nextechinvest, Piramed Pharma) hold stock and/or directorship from the indicated institutions. All other authors declare no competing interests. No authors declare relevant honoraria for speaking or patents.